# Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

> **NCT06483347** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 90 (estimated)

## Conditions studied

- Lung Cancer
- Inoperable Disease

## Interventions

- **DRUG:** ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab

## Key facts

- **NCT ID:** NCT06483347
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2028-12-30
- **Final completion:** 2033-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06483347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06483347, "Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06483347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*